Vidac Pharma Holding PLC (XETR:T9G) Completes Last Visit in Phase 2b AK Trial
Vidac Pharma Holding PLC reached last patient last visit in its randomized, double-blind, placebo-controlled Phase 2b study of topical VDA-1102 in highly proliferative actinic keratosis. No treatment-related serious adverse events reported; results expected in coming weeks.Material DetailsContext b…